1008 related articles for article (PubMed ID: 23611684)
61. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
62. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
63. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
[TBL] [Abstract][Full Text] [Related]
64. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
Elayan MM; Horowitz JG; Magraner JM; Shaughnessy PJ; Bachier C
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1921-5. PubMed ID: 26033279
[TBL] [Abstract][Full Text] [Related]
65. Mobilization of hematopoietic stem cells with lenograstim in multiple myeloma patients: Prospective multicenter observational study (KMM122).
Jung EH; Byun JM; Shin DY; Do YR; Jo JC; Lee SM; Yoon SS
Cancer Med; 2023 Apr; 12(8):9186-9193. PubMed ID: 36951655
[TBL] [Abstract][Full Text] [Related]
66. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Bhutani D; Zonder J; Valent J; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Lum L; Ratanatharathorn V; Uberti J; Abidi MH
Support Care Cancer; 2013 Sep; 21(9):2437-42. PubMed ID: 23591714
[TBL] [Abstract][Full Text] [Related]
67. Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Zeller W; Kröger N; Berger J; Krueger W; Dierlamm J; Stockschläder M; Gutensohn K; Hossfeld DK; Zander AR
J Hematother Stem Cell Res; 1999 Oct; 8(5):539-46. PubMed ID: 10791904
[TBL] [Abstract][Full Text] [Related]
68. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
69. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
[TBL] [Abstract][Full Text] [Related]
70. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
[TBL] [Abstract][Full Text] [Related]
71. High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma.
Hyun SY; Cheong JW; Kim SJ; Min YH; Yang DH; Ahn JS; Lee WS; Ryoo HM; Do YR; Lee HS; Lee JH; Oh SY; Suh C; Yhim HY; Kim JS
Biol Blood Marrow Transplant; 2014 Jan; 20(1):73-9. PubMed ID: 24141009
[TBL] [Abstract][Full Text] [Related]
72. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields.
Weaver CH; Tauer K; Zhen B; Schwartzberg LS; Hazelton B; Weaver Z; Lewkow L; Allen C; Longin K; Buckner CD
J Hematother; 1998 Jun; 7(3):241-9. PubMed ID: 9621257
[TBL] [Abstract][Full Text] [Related]
73. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
[TBL] [Abstract][Full Text] [Related]
74. Chemomobilization with high-dose etoposide and G-CSF results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report from a single institution study and review.
Ozkan HA; Bal C; Gulbas Z
Eur J Haematol; 2014; 92(5):390-7. PubMed ID: 24400988
[TBL] [Abstract][Full Text] [Related]
75. Changes in reticulocyte fractions during peripheral stem cell harvesting: role in monitoring stem cell collection.
Remacha AF; Martino R; Sureda A; Sarda MP; Solá C; Tugues D; Amill B; Garcia J; Oliver A
Bone Marrow Transplant; 1996 Feb; 17(2):163-8. PubMed ID: 8640161
[TBL] [Abstract][Full Text] [Related]
76. Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF.
Delamain MT; Metze K; Marques JF; Reis AR; De Souza CA; Lorand-Metze I
Transfus Apher Sci; 2006 Feb; 34(1):33-40. PubMed ID: 16376618
[TBL] [Abstract][Full Text] [Related]
77. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation.
Wuchter P; Ran D; Bruckner T; Schmitt T; Witzens-Harig M; Neben K; Goldschmidt H; Ho AD
Biol Blood Marrow Transplant; 2010 Apr; 16(4):490-9. PubMed ID: 19925876
[TBL] [Abstract][Full Text] [Related]
78. A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization.
Manko J; Walter-Croneck A; Jawniak D; Grzasko N; Gorska-Kosicka M; Cioch M; Dmoszynska A
Pharmacol Rep; 2014 Apr; 66(2):239-42. PubMed ID: 24911076
[TBL] [Abstract][Full Text] [Related]
79. Lenograstim versus filgrastim in mobilization before autologous hematopoietic stem cell transplantation in patients with multiple myeloma and lymphoma - Single center experience.
Sarıcı A; Erkurt MA; Bahçecioğlu ÖF; Biçim S; Berber İ; Gök S; Kaya E; Özgül M; Kuku İ
Transfus Apher Sci; 2021 Aug; 60(4):103127. PubMed ID: 33863669
[TBL] [Abstract][Full Text] [Related]
80. The use of G-CSF during first line chemotherapy adversely affects the yield of PBSC mobilization in non-Hodgkin's lymphoma patients.
Damiani D; Grimaz S; Sperotto A; Geromin A; Skert C; Cerno M; Rinaldi C; Fanin R
Adv Clin Path; 2002 Jan; 6(1):11-6. PubMed ID: 17582943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
